An interventional study of Active Comparator: Experimental Group 1 and Experimental: Experimental Group 2 in To be Approved by the Ethics Committee, sponsored by University of Alcala. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by University of Alcala · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Pelvic Pain with a site in Spain — 6 open to participants now, 6 under way, none of them phase 3. Pelvic Pain · Spain.
Among the 27 studies in Pelvic Pain with a site in Spain, this one is the 11th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, and was the 17th registered.
377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.
Browse Pelvic Pain studies →6 of the 27 studies in Pelvic Pain with a site in Spain are open now. Recruiting first, the newest first:
University of Alcala · Sites in Spain
Ages 18–40 · Women only
Instituto Sexológico Murciano · Sites in Spain
Ages 18+ · Women only
Hospital Universitari de Bellvitge · Sites in Spain
Ages 18–45 · Women only
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+ · Women only · Healthy volunteers
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 74 is above the median of 60 across 278 interventional studies indexed under Pelvic Pain.
Median enrollment 69 across the 22 interventional studies, 133 across the 5 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
University of Alcala is the lead sponsor of 128 studies on the registry; 36 are open to participants now.
University of Alcala has 3 studies filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Pelvic Pain with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06955221Hospital Universitari de BellvitgeEffect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Pelvic Pain with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
About 30% of women experience pain in the perineum and pelvic region one year after the vaginal labor, rising up to 50% when it is triggered during vaginal penetration, called this pain as dyspareunia. An early physiotherapy treatment could be the solution to the pain relief of these women. Thus, the objectives of the present randomised clinical trail are (i) to determine the effectiveness of a physiotherapy treatment based on education therapeutic, the treatment of myofascial pain syndrome (MPS) of the pelvic floor muscles (PFM), and PFM specific training with or without radiofrequency in reducing pain and improving sexual function; and, (ii) to know the facilitating factors and barriers in adherence and perceived self-efficacy towards physiotherapy treatment of women with pelviperineal pain in the postpartum.
Methodology: randomized clinical trial with examinator blinding and two parallel groups, followed by a qualitative study. Thirty eight women per group will be needed with postpartum pelviperineal pain between 8 weeks after labour, with intensity ≥ 4 cm on the visual analogue scale. The assignment will be random to an Experimental 1 group based on therapeutic education, plus conservative and invasive treatment of MPS and specific PFM exercise versus an Experimental 2 group consisted in the same treatment plus non-ablative radiofrequency treatment. In both cases, 12 individual supervised sessions will be held by a physiotherapist specialized in women's health, with evaluations pre- and post-intervention, at 3 and 6 months. The outcome variables will be the intensity of the pain, the presence of MPS at PFM, the PFM contraction quality, sexual function and specific quality of life. The qualitative study will be carried out in the assessment 6 months post-intervention, through interviews semi-structured and focus groups. The interviews will be guided with previous questions established, recorded, transcribed and thematically analyzed by a panel of experts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There will be 12 individual sessions guided by a physiotherapist specialized in Women's Health. The approximate duration will be 45 minutes/session, 2 times a week for 6 weeks. The intervention will consist of a multimodal physiotherapy treatment based on therapeutic patient education, specific PFM exercises, and conservative and invasive treatment of the MPS. Pre- and post-intervention assessments will be carried out, and at 3 and 6 months after the intervention, by an examining physiotherapist who will be blinding for the intervention group.
Other: Active Comparator: Experimental Group 1
There will be 12 individual sessions guided by a physiotherapist specialized in Women's Health. The approximate duration will be 45 minutes/session, 2 times a week for 6 weeks. The intervention will consist of a multimodal physiotherapy treatment based on therapeutic patient education, specific PFM exercises, conservative and invasive treatment of the MPS and non-ablative radiofrequency. Pre- and post-intervention assessments will be carried out, and at 3 and 6 months after the intervention, by an examining physiotherapist who will be blinding for the intervention group.
Other: Experimental: Experimental Group 2
Multimodal physiotherapy treatment composed of: Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain. Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity. Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.
Multimodal physiotherapy treatment composed of: Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain. Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity. Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique. Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes.
Pain intensity through the Verbal Numerical Scale (0 no pain, and 10 the most bearable pain)
intensity, behavior and location (pain body chart).
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Sexual function
Self-completion of the FSFI questionnaire, which evaluates sexual function based on 6 domains: desire, excitement, lubrication, orgasm, satisfaction and pain. The maximum score is 36, considering sexual dysfunction a value \>27.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Pelvic floor dysfunction symptoms
Presence of urinary, intestinal and/or symptoms suggestive of prolapse
Time frame: Pre-treatment, post-treatment (after 12 sessions of physiotherapy treatment which will last approximately 3 months after starting the study), 3 and 6 months after treatment
PFM capacity of contraction through Modified Oxford Scale (0 no contraction, 5 strong contraction)
Intravaginal palpation of pelvic floor muscles with one or two fingers.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
PFM capacity of relaxation (yes or no)
Intravaginal palpation of pelvic floor muscles with one or two fingers.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
PFM basal tone in grams
Intravaginal dynamometry
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
PFM muscle strength in grams
Intravaginal dynamometry
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Distance of the urogenital hiatus in milimeters
Assessment through transperineal ultrasound of the distance of the urogenital hiatus at rest, during a strong PFM contraction and during a pushing effort.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Presence of MPS in PFM and abdominal muscles
Following the diagnostic criteria of Travel and Simons.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Specific quality of life and impact of Pelvoc floor Disfunction using questionnaires: PFDI-20 and PFIQ-7
Through the questionnaires: Pelvic Floor Distress Inventory short version (PFDI-20) and Pelvic Floor Impact Questionnaire short form (PFIQ-7). In both questionnaires, the scores range between 0 and 300, where a higher score indicates more distress and more impact on quality of life.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Self-efficacy
Through Broome Pelvic Muscle Self-Efficacy Scale. The score ranges from 0 to 100, where 100 implies greater self-efficacy.
Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment
Started Jun 2023 (actual). Primary completion is estimated for Oct 2024, 16 months after the start.
Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 16 months is close to that.
Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.